Valuation: Cerus Corporation

Market Cap 49Cr 43Cr 40Cr 36Cr 68Cr 4.61TCr 70Cr 476.36Cr 190.96Cr 2.44TCr 183.07Cr 179.15Cr 7.73TCr P/E 2026 *
-74.3x
P/E 2027 * -322x
Enterprise Value 49Cr 44Cr 40Cr 37Cr 69Cr 4.66TCr 70Cr 481.24Cr 192.92Cr 2.46TCr 184.94Cr 180.99Cr 7.81TCr EV / Sales 2026 *
2.03x
EV / Sales 2027 * 1.8x
Free-Float
96.39%
Yield 2026 *
-
Yield 2027 * -
1 day+3.21%
1 week-0.21%
Current month+5.92%
1 month+5.92%
3 months+10.27%
6 months-11.21%
Current year+17.23%
1 week 2.11
Extreme 2.11
2.52
1 month 2.11
Extreme 2.11
2.52
Current year 1.62
Extreme 1.62
3.47
1 year 1.38
Extreme 1.38
3.47
3 years 1.12
Extreme 1.12
3.47
5 years 1.12
Extreme 1.12
7.98
10 years 1.12
Extreme 1.12
8.87
Manager TitleAgeSince
Chief Executive Officer 51 01/07/2026
Chief Tech/Sci/R&D Officer 82 01/07/2015
Director of Finance/CFO 54 04/05/2009
Director TitleAgeSince
Chairman 59 16/03/2026
Director/Board Member 72 24/03/2014
Director/Board Member 51 01/07/2026
Date Insider Type Main position Quantity % Market Cap. Importance
17/08/26 Sell

General Counsel

-30,000 0.0150%
16/07/26 Sell

Chief Executive Officer

-16,666 0.0083%
01/07/26 Free

Chief Executive Officer

9,24,215 0.4613%
Change 5-day change 1-year change 3-year change Capi.($)
+3.21%-0.21%+66.55%+39.60% 49Cr
+5.59%+12.54%-8.18%+20.52% 20TCr
+6.15%+10.74%+16.08%+44.65% 13TCr
+9.37%+11.73%-6.33%+22.96% 13TCr
+0.82%+6.99%-39.72%+10.42% 9.75TCr
+3.96%+9.14%+2.75%+81.38% 6.76TCr
+5.56%+7.19%+16.84%-19.20% 5.7TCr
+3.94%+24.10%-3.26%+62.72% 5.5TCr
-1.39%-8.56%-2.92%+53.39% 5.12TCr
-0.96%+6.40%+4.48%-6.24% 3.74TCr
Average +2.98%+7.71%+4.63%+31.02% 8.24TCr
Weighted average by Cap. +3.72%+9.78%-3.94%+29.37%

Financials

2026 *2027 *
Net sales 24Cr 22Cr 20Cr 18Cr 34Cr 2.29TCr 35Cr 236.83Cr 95Cr 1.21TCr 91Cr 89Cr 3.84TCr 26Cr 24Cr 22Cr 20Cr 37Cr 2.49TCr 38Cr 257.64Cr 103.28Cr 1.32TCr 99Cr 97Cr 4.18TCr
Net income -73.05L -65.09L -59.7L -54.25L -1.02Cr -69Cr -1.04Cr -7.13Cr -2.86Cr -37Cr -2.74Cr -2.68Cr -115.75Cr -34.9L -31.1L -28.52L -25.92L -48.73L -33Cr -49.84L -3.41Cr -1.37Cr -17Cr -1.31Cr -1.28Cr -55Cr
Net Debt 50L 44.56L 40.86L 37.13L 69.81L 47Cr 71.4L 4.88Cr 1.96Cr 25Cr 1.88Cr 1.84Cr 79Cr -1.3Cr -1.16Cr -1.06Cr -96.54L -1.81Cr -122.86Cr -1.86Cr -13Cr -5.09Cr -65Cr -4.88Cr -4.78Cr -205.99Cr
Projected Income Statement - Annual - Cerus Corporation
Logo Cerus Corporation
Cerus Corporation is a biomedical products company. The Company is focused on developing and commercializing the INTERCEPT Blood System to enhance blood safety. The INTERCEPT Blood System, which is based on its proprietary technology for controlling biological replication, is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. Its INTERCEPT Blood System is intended for use with blood components and certain of their derivatives: platelets, plasma, red blood cells and to produce INTERCEPT Fibrinogen Complex (IFC), and pathogen reduced plasma, cryoprecipitate reduced. The INTERCEPT Blood System for Cryoprecipitation uses its plasma system to produce IFC for the treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency. In addition, the INTERCEPT Blood System for Cryoprecipitation is used to produce pathogen reduced plasma, cryoprecipitate reduced.
Employees
268
Date Price Change Volume
04/26/04 $2.415 +3.21% 25,12,557
03/26/03 $2.340 -0.85% 34,97,692
02/26/02 $2.360 +3.51% 39,84,992
30/26/30 $2.280 -6.56% 15,03,449
29/26/29 $2.440 +0.83% 13,53,264
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
AA
MarketScreener Ratings - Cerus Corporation
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
2.415USD
Average target price
5.125USD
Spread / Average Target
+112.22%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Cerus Corporation
  1. Stock Market
  2. Stocks
  3. CERS Stock